|Public Act* No.||Description||Effective Date|
|Prescribing Controlled Substances|
|PA 247 of 2017||Requires prescribers to have a bona fide prescriber-patient relationship in order to prescribe a controlled substance.||Jan 2019|
|PA 251 of 2017||Limits acute pain opioid prescriptions to 7-day period and supply. Allows pharmacists to partially fill a controlled substance (Schedule 2) prescription.||July 2018|
|PA 248 of 2017||Requires prescriber to obtain and review a MAPS report prior to prescribing or dispensing a controlled substance prescription exceeding a 3-day supply.||June 2018|
|PA 246 of 2017||Requires prescriber to educate the patient and have an attestation form signed prior to issuing a control substance prescription.||June 2018|
|PA 250 of 2017||Requires professionals treating a patient for an opioid-related overdose to provide information on Substance Use Disorder (SUD) treatment services.||March 2018|
|Medication Assisted Treatment|
|PA 19 of 2022||Removes prior authorization on medications used to treat opioid use disorder, including buprenorphine, for patients with Michigan Medicaid.||June 2022|
|DHHS (Federal)||Requires prescribers to obtain an X-waiver before prescribing buprenorphine, but|
requirements for training and the provision of psychosocial services have been
|PA 176 of 2022||Allows the distribution of naloxone community-based organizations, such as a nonprofit organizations or social service providers, under a standing order and protects from liability.||July 2022|
|PA 39 of 2019||Allows agencies to purchase and possess an opioid antagonist and distribute it to a trained employee. Allows the employee to administer it to an individual who they believe is experiencing an opioid-related overdose.||Sept 2019|
|PA 383 of 2016||Allows pharmacists to dispense Naloxone without an individual prescription and without identifying a particular patient (aka Naloxone standing order).||March 2017|
|PA 307 of 2016||Protects from liability individuals who administer naloxone in good faith to someone whom they believe to be suffering an opioid-related overdose.||Jan 2017|
|PA 42, PA 43, PA 44 of 2022||Requires insurer to provide non-opioid directive form upon enrollment/renewal;|
requires insurer to post form on website; requires hospital to post form on website.
|PA 41 of 2022||Provides exception to non-opioid directive that allows certain prescribers to administer opioids for intraoperative use.||March 2022|
|PA 554 of 2018||Allows patients to fill out a state form that directs health professionals and emergency medical services personnel to not administer opioids to them.||March 2019|
Last updated October 2022.
*A public act is a bill that has been approved by the Legislature and signed into law. This version is as originally passed and does not include updates from subsequent legislation (see Michigan Compiled Laws).
**Naloxone, also known by its brand name Narcan®, is a medication intended for the reversal of an overdose that occurs after consumption or use of one or more opioids or opioid-related substances.
Cite this work:
OPEN: Opioid Prescribing Engagement Network. (2022). Current Michigan Opioid Policy. Retrieved from https://doi.org/10.56137/OPEN.000082